MVT-602: Dosing Protocols
Dosing guidelines, reconstitution, and administration information
๐TL;DR
- โข2 dosing protocols documented
- โขReconstitution instructions included
- โขStorage: Investigational compound; storage managed under controlled pharmaceutical conditions by clinical trial sites. No commercial storage guidelines.
Protocol Quick-Reference
Oocyte maturation trigger during IVF/medically assisted reproduction
Dosing
Amount
Single subcutaneous injection (dose escalation studied)
Frequency
Single dose
Duration
Single administration
Administration
Route
SCSchedule
Single dose
Timing
Administered as a single injection to trigger oocyte maturation; LH surge peaks at 21-22 hours post-dose
Cycle
Duration
Single dose per IVF cycle
Repeatable
Yes
โ๏ธ Suggested Bloodwork (3 tests)
LH and FSH
When: Baseline
Why: Baseline gonadotropin levels
Estradiol
When: Baseline
Why: Assess ovarian stimulation status
LH
When: 12-24 hours post-dose
Why: Confirm LH surge onset and magnitude
๐ก Key Considerations
- โInvestigational compound: not approved for clinical use in any country
- โDesigned to reduce OHSS risk compared to hCG triggers by working through endogenous GnRH-LH pathway
- โNo pregnancy outcome data available; efficacy in actual IVF egg retrieval cycles not yet demonstrated
Unlock dosing protocols
Free access to research-backed dosing information for all peptides.
150+ peptide profiles ยท 30+ comparisons ยท 18 research tools
| Purpose | Dose | Frequency | Duration | Notes |
|---|---|---|---|---|
| Phase 1: LH Surge Characterization (Follicular Phase) | Single subcutaneous injection at escalating doses in healthy premenopausal women during the follicular phase. | Single dose | Single administration with pharmacodynamic monitoring over 48 hours | Dose-related LH increases observed. Prolonged LH surge with peak at 21-22 hours vs 4.7 hours for kisspeptin-54. |
| Phase 2a: After Ovarian Stimulation | Single subcutaneous injection after minimal ovarian stimulation to model medically assisted reproduction endocrine milieu. | Single dose | Single administration with endocrine monitoring | Confirmed prolonged LH surge profile in ovarian stimulation context. High rates of ovulation reported. |
Unlock full dosage protocols
Free access to complete dosing tables and protocol details.
150+ peptide profiles ยท 30+ comparisons ยท 18 research tools
๐Reconstitution Instructions
MVT-602 is an investigational compound administered as a subcutaneous injection. Formulation details not publicly disclosed. Clinical trial supplies managed by sponsor.
Recommended Injection Sites
- โSubcutaneous injection (specific sites not specified in published data)
๐งStorage Requirements
Investigational compound; storage managed under controlled pharmaceutical conditions by clinical trial sites. No commercial storage guidelines.
Community Dosing Protocols
Compare these clinical doses with what community members report using.
0View community protocolsResearch Tools
Before You Begin
Review safety warnings and contraindications before starting any protocol.
Important Disclaimer#
MVT-602 is an investigational compound not approved for clinical use. All dosing information is from published clinical trial data and is provided for educational purposes only.
Clinical Trial Dosing#
Phase 1 Study#
The Phase 1 study evaluated single subcutaneous doses of MVT-602 in healthy premenopausal women during the follicular phase. Dose-related increases in LH were observed, with the LH surge peaking at 21-22 hours after administration (versus 4.7 hours for kisspeptin-54) and an approximately 4-fold greater LH area under the curve.
Phase 2a Study#
The Phase 2a study administered MVT-602 after minimal ovarian stimulation. The prolonged LH surge profile was confirmed, with high rates of ovulation and an LH surge closely resembling the natural mid-cycle surge.
Intended Clinical Application#
MVT-602 is being developed as a single-injection oocyte maturation trigger for IVF, replacing hCG or GnRH agonists at the end of controlled ovarian stimulation. The expected clinical protocol would involve standard gonadotropin stimulation followed by a single MVT-602 injection when follicles reach maturity, with egg retrieval approximately 36 hours later.
| Trigger | Mechanism | LH Duration | OHSS Risk |
|---|---|---|---|
| hCG | Direct LH receptor activation | Days (long hCG half-life) | High |
| GnRH agonist | Pituitary LH flare | Brief (4-12 hours) | Low |
| Kisspeptin-54 | Endogenous GnRH-LH pathway | ~4.7 hours | Low |
| MVT-602 | Endogenous GnRH-LH pathway | ~21-22 hours | Expected low |
Administration#
Administered as a single subcutaneous injection. Detailed administration instructions have not been published from clinical trial protocols.
Dosing Context#
MVT-602 belongs to the Reproductive category of research peptides. Dosing protocols for MVT-602 are derived from available clinical trial data. These protocols are provided for research reference only and do not constitute medical advice. Actual dosing decisions should be made by qualified healthcare providers based on individual patient factors.
Research Protocols#
The following dosing protocols have been documented in clinical research for MVT-602:
Phase 1: LH Surge Characterization (Follicular Phase)#
Dose: Single subcutaneous injection at escalating doses in healthy premenopausal women during the follicular phase.
Frequency: Single dose
Duration: Single administration with pharmacodynamic monitoring over 48 hours
Dose-related LH increases observed. Prolonged LH surge with peak at 21-22 hours vs 4.7 hours for kisspeptin-54.
Phase 2a: After Ovarian Stimulation#
Dose: Single subcutaneous injection after minimal ovarian stimulation to model medically assisted reproduction endocrine milieu.
Frequency: Single dose
Duration: Single administration with endocrine monitoring
Confirmed prolonged LH surge profile in ovarian stimulation context. High rates of ovulation reported.
Reconstitution and Preparation#
MVT-602 is an investigational compound administered as a subcutaneous injection. Formulation details not publicly disclosed. Clinical trial supplies managed by sponsor.
Injection Sites#
Recommended injection sites for MVT-602 include:
- Subcutaneous injection (specific sites not specified in published data)
Site rotation is recommended to minimize local tissue reactions and ensure consistent absorption.
Storage Requirements#
Investigational compound; storage managed under controlled pharmaceutical conditions by clinical trial sites. No commercial storage guidelines.
Related Reading#
Subscribe to see vendor options
Free access to verified vendor scores, pricing, and suppliers.
150+ peptide profiles ยท 30+ comparisons ยท 18 research tools
Protocol updates
Get notified when we update dosing protocols or publish related comparisons.
Frequently Asked Questions About MVT-602
Explore Further
Medical Disclaimer
This website is for educational and informational purposes only. The information provided is not intended to diagnose, treat, cure, or prevent any disease. Always consult with a qualified healthcare professional before using any peptide or supplement.